Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary

  • Andrea Kokorovic
  • Alan I. So
  • Hosam Serag
  • Christopher French
  • Robert J. Hamilton
  • Jason P. Izard
  • Jasmir G. Nayak
  • Fréderic Pouliot
  • Fred Saad
  • Bobby Shayegan
  • Armen Aprikian
  • Ricardo A. Rendon
Keywords: ADT, prostate cancer, CV risk, bone health, HRQOL

Abstract

Androgen deprivation therapy (ADT) plays an important role in the contemporary management of prostate cancer (PCa) across various stages of the disease. While ADT remains a highly effective treatment for PCa, it is not curative, and its use is associated with significant adverse events that span across various organ systems.

Published
2021-05-31
How to Cite
Kokorovic, A., So, A. I., Serag, H., French, C., Hamilton, R. J., Izard, J. P., Nayak, J. G., Pouliot, F., Saad, F., Shayegan, B., Aprikian, A., & Rendon, R. A. (2021). Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies – Executive summary. Canadian Urological Association Journal, 15(6), 159-61. https://doi.org/10.5489/cuaj.7357
Section
CUA Guideline